Pandurang Kolekar

Has grant

Sr. Computational Research Scientist

St. Jude Children's Research Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Design and development of Inter-arrival time based statistical algorithm for clustering, phylogeny and genotyping of viruses

Open Date: 2009-08-01

Close Date: 2014-07-01

Articles (7)

Year:

2026

Relapse remains the leading cause of mortality in pediatric acute myeloid leukemia (AML), yet the genetic changes contributing to relapse remain incompletely defined. To address this gap, we performed whole-genome sequencing and targeted-capture sequencing on 39 diagnosis–relapse and 2 relapse–relapse pairs of pediatric AML. Mutational burden increased at relapse, largely reflecting spontaneous mutagenesis, whereas therapy-related signatures were rarely observed and only occasionally associated with pathogenic mutations. Although recurrently enriched mutations at relapse included those in FLT3 , WT1 , and TP53 , relapse-fated subclones were frequently marked only by non-pathogenic or non-coding variants. Longitudinal deep sequencing in eight patients showed rapid depletion of major clones after induction therapy, whereas subclones often displayed variable chemosensitivity. Relapse-specific mutations emerged only late or remained undetectable during remission, suggesting that clonal selection of pre-existing clones is the predominant mechanism of relapse. Transcriptome analysis of paired RNA sequencing data revealed no differentially expressed genes, but gene set enrichment analysis and CIBERSORT deconvolution in each pair uncovered heterogeneous trajectories to relapse. Although relapse is often attributed to the emergence of stem-like phenotypes, our data demonstrate that transcriptional evolution is more diverse: some cases acquired stem-like features, whereas others showed partial differentiation, which was confirmed by re-analysis of a public single cell RNA sequence dataset. These changes were largely constrained by baseline differentiation states at diagnosis. Together, our data indicate that pediatric AML relapse arises through selection of pre-existing clones with diverse trajectories, underscoring the need to target both stem-like and differentiated populations to achieve durable cures.

Year:

2025

We provide data showing the germline predisposition structural variants (SV) involving MYCN and RAF1::TMEM40 reported by Gillani et al. (2025) in pediatric solid tumors are confounded by circulating tumor DNA (ctDNA) and enrichment for Hispanic or Latino ancestry, respectively. We suggest that future germline studies should ensure analyses of tumor-in-normal contamination for non-polymorphic markers and careful examination of population stratification for polymorphic markers to ensure clinical relevance.

Year:

2025

Purpose: The purpose of the study was to design a pan-cancer gene panel for childhood malignancies and validate it using clinically characterized patient samples. Experimental Design: In addition to 5,275 coding exons, SJPedPanel also covers 297 introns for fusions/structural variations and 7,590 polymorphic sites for copy-number alterations. Capture uniformity and limit of detection are determined by targeted sequencing of cell lines using dilution experiment. We validate its coverage by in silico analysis of an established real-time clinical genomics (RTCG) cohort of 253 patients. We further validate its performance by targeted resequencing of 113 patient samples from the RTCG cohort. We demonstrate its power in analyzing low tumor burden specimens using morphologic remission and monitoring samples. Results: Among the 485 pathogenic variants reported in RTCG cohort, SJPedPanel covered 86% of variants, including 82% of 90 rearrangements responsible for fusion oncoproteins. In our targeted resequencing cohort, 91% of 389 pathogenic variants are detected. The gene panel enabled us to detect ∼95% of variants at allele fraction (AF) 0.5%, whereas the detection rate is ∼80% at AF 0.2%. The panel detected low-frequency driver alterations from morphologic leukemia remission samples and relapse-enriched alterations from monitoring samples, demonstrating its power for cancer monitoring and early detection. Conclusions: SJPedPanel enables the cost-effective detection of clinically relevant genetic alterations including rearrangements responsible for subtype-defining fusions by targeted sequencing of ∼0.15% of human genome for childhood malignancies. It will enhance the analysis of specimens with low tumor burdens for cancer monitoring and early detection.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (10)

Sharon Diskin

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Seth Karol

Associate Member, Leukemia & Lymphoma Division

St. Jude Children's Research Hospital

UNITED STATES
View details

Csaba P. Kovesdy

-

UNITED STATES
View details

Samuel Brady

Associate Professor, Clinical Medical Physicist

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Chi-Yang Chiu

Associate professor

University of Tennessee Health Science Center

UNITED STATES
View details

Esther Obeng

Associate Professor

Emory University

UNITED STATES
View details

John Maris

PI

University of Pennsylvania

UNITED STATES
View details

Tanja A. Gruber

Stanford University

UNITED STATES
View details

Jinghui Zhang

Professor

St. Jude Children's Research Hospital

UNITED STATES
View details

Lu Wang

Medical Director, Molecular Pathology

St. Jude Children's Research Hospital

UNITED STATES
View details